Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993827 | 1.00 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| Alcohol SCHEMBL28875867 | 0.88 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL125255 | 0.87 | ALDH1A1 (0.57) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL29729780 | 0.87 | ALDH1A1 (0.57) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL6772494 | 0.85 | SLC6A4 (0.49) | SLC6A4SLC6A2ALDH1A1TSHRKDM4E | |
| SCHEMBL8677184 | 0.82 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL11632956 | 0.80 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3ALDH1A1LMNA | |
| SCHEMBL29366632 | 0.79 | APOBEC3G (0.60) | ALDH1A1TSHRCYP2D6LMNAGAA | |
| SCHEMBL41139 | 0.79 | APOBEC3G (0.60) | ALDH1A1TSHRCYP2D6LMNAGAA | |
| SCHEMBL13360178 | 0.79 | HSD17B3 (0.43) | SLC6A4ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4103542-A1 | NANOMATERIALS | Guide Therapeutics, LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115175894-A | Nano material | 盖德治疗有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3897841-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113226470-A | Rifamycin analogs and antibody-drug conjugates thereof | 瑞泽恩制药公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210230112-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2021-07-29 | — | — | US | disclosed |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| WO-2020132483-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-5723398-A | CATALYST OF METAL CYCLOPENTADIENYL COMPLEX FOR POLYMERIZATION | THE DOW CHEMICAL COMPANY (US) | 1998-03-03 | — | — | US | disclosed |
| US-5494874-A | TITANIUM COMPLEXES WITH A COCATALYST AS POLYMERIZATION CATALYSTS | THE DOW CHEMICAL COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| US-5374696-A | Catalyzing the addition polymerization in presence of titanium metal complexes with cocatalysts | THE DOW CHEMICAL COMPANY (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0270091-B1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICAMENTS OF THERAPEUTIC VALUE, AND INTERMEDIATES FORMED DURING SAID PROCESSES | TANABE SEIYAKU CO., LTD. (JP) | 1992-11-11 | — | — | EP | disclosed |
| US-5053417-A | Antiulcer agents | TANABE SEIYAKU CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-5002945-A | Antiulcer agents | TANABE SEIYAKU CO. LTD. (JP) | 1991-03-26 | — | — | US | disclosed |
| US-4996217-A | Antiulcer agents | TANABE SEIYAKU COMPANY, LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| EP-0270091-A1 | Imidazole derivatives, processes for the preparation of the same, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments of therapeutic value, and intermediates formed during said processes | TANABE SEIYAKU CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230112-A1 | NANOMATERIALS | NPC1, NPC1L1, FABP1 | SLC6A4 2588/4885SLC6A2 1535/4885SLC6A3 2481/4885 |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | SLC6A4 3414/4885SLC6A2 2695/4885SLC6A3 3296/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | SLC6A4 1940/4885SLC6A2 791/4885SLC6A3 2617/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | SLC6A4 3414/4885SLC6A2 2695/4885SLC6A3 3296/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | SLC6A4 2588/4885SLC6A2 1535/4885SLC6A3 2481/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | SLC6A4 3414/4885SLC6A2 2695/4885SLC6A3 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.